glp-1 agonists with cardiovascular benefit Bridging the gap between GLP1-receptor and outcomes: evidence for the role of tirzepatide | Cardiovascular Diabetology The conversation around GLP-1 medications

2 , 3 Additionally, weight regain after treatment discontinuation and reductions in lean mass have raised new clinical concerns, while issues surrounding cost and accessibility present barriers to the widespread adoption of these drugs.4, 5, 6, 7 This review explores the evolving role of GLP-1 RAs, highlighting their benefits beyond weight loss, key safety and policy considerations, and future directions for optimizing their use

6 As more positive health data emerges from trials of weight loss products, the pressure increases on payers and employers to cover these products

95% CI 31.99 to 7.03

[Google Scholar] 109

Ensuring Quality and Efficacy of GLP-1 Agonists: Analytical Challenges and Solutions in Therapeutic Peptide Production Glucagon-like peptide-1 (GLP-1) agonists represent an exciting class of drugs that have gained significant attention in recent years for their potential to treat type 2 diabetes mellitus (T2DM) and obesity